收稿日期: 2023-03-27
网络出版日期: 2023-11-22
Treatment course of sensitive tuberculosis： From 24 months to 2 months
Received date: 2023-03-27
Online published: 2023-11-22
李亮 , 刘宇红 . 敏感结核病治疗：从24个月到2个月[J]. 实用医学杂志, 2023 , 39(19) : 2421 -2423 . DOI: 10.3969/j.issn.1006-5725.2023.19.001
The results of a clinical trial using an 8?week combination regimen of new drugs to treat sensitive tuberculosis， published by The New England Journal of Medicine in March 2023， have raised new expectations for further shortening the course of treatment for sensitive tuberculosis. Whether the treatment of sensitive TB must follow the standard 6-month chemotherapy regimen？ This article reviews the historical evolution of the treatment plan for sensitive tuberculosis，and Propose thoughts and prospects for future treatment directions based on the current situation in China。
| 1 | BAGCCHI S. Global tuberculosis report 2022［J］. Lancet Microbe， 2023，4（1）：e20 |
| 2 | WHO consolidated guidelines on tuberculosis： module 4： treatment： drug-susceptible tuberculosis treatment［EB/OL］. Geneva： World Health Organization， 2022. |
| 3 | PATON N I， COUSINS C， SURESH C，et al. Treatment strategy for rifampin-susceptible tuberculosis［J］. N Engl J Med， 2023， 388（10）：873-887. |
| 4 | Streptomycin treatment of pulmonary tuberculosis， a medical research council investigation［J］. Br Med J，1948，2（4582）：769-782 |
| 5 | World Health Organization tuberculosis program for 1950［J］. Public Health Rep，1949，64（35）：1117-1123. |
| 6 | Second East African/British Medical Research Council Study. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report［J］. Am Rev Respir Dis， 1976， 114（4）：471-475. |
| 7 | HART P D. Chemotherapy of tuberculosis； research during the past 100years［J］. Br Med J，1946，2（4482）：805-810. |
| 8 | World Health Organization. Global tuberculosis report 2021［EB/OL］. Geneva： World Health Organization，2021. |
| 9 | Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis［J］. Am Rev Respir Dis， 1979， 119（4）：579-585. |
| 10 | Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council［J］. Am Rev Respir Dis， 1986，133（5）：779-783. |
| 11 | Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis： the results up to 30 months［J］. Tubercle， 1981， 62（2）：95-102. |
| 12 | A controlled clinical trial of oral short-course regimens in the treatment of sputum positive pulmonary tuberculosis. Tuberculosis Research Centre［J］. Int J Tuberc Lung Dis 1997， 1（6）：509-517. |
| 13 | GILLESPIE S H， CROOK A M， MCHUGH T D，et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis［J］. N Engl J Med， 2014，371（17）：1577–1587. |
| 14 | DORMAN S E， NAHID P， KURBATOVA E V，et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis［J］. N Engl J Med， 2021，384（18）：1705-1718. |
/
| 〈 |
|
〉 |